Critical Quality Attributes (CQAs) in Formulation Development
In pharmaceutical development, understanding your Critical Quality Attributes (CQAs) is not just regulatory jargon — it’s the foundation of Quality by Design (QbD).
According to ICH Q8(R2), a CQA is any physical, chemical, biological, or microbiological characteristic that must be controlled within an appropriate range to ensure the desired product quality. These attributes have a direct impact on the product’s safety, efficacy, and performance.
But identifying CQAs isn’t guesswork — it’s a strategic process.
Here’s how we approach it:
- Start with the Quality Target Product Profile (QTPP)
Your QTPP defines what the product is meant to do — its intended use, route of administration, dosage form, and therapeutic goals. From here, you can map back to which attributes must be critically controlled to meet these goals. - Use prior knowledge + scientific tools
Leverage literature, platform technology, and historical data. Combine that with risk assessment tools like FMEA, Ishikawa diagrams, or Pareto analysis to filter out which material attributes and process parameters truly affect quality. - Refine continuously
CQAs aren’t static. As you move from lab scale to commercial, your understanding deepens — and your list of CQAs evolves. That’s the power of QbD thinking — it’s iterative and knowledge-driven.
Examples of typical CQAs:
- Purity and assay (API and impurities)
- Dissolution profile (especially for BCS II and IV)
- Content uniformity (critical for low-dose formulations)
- Sterility and particulate matter (for injectables)
- Water content (affecting stability)
Why CQAs matter:
- They drive your formulation design
- They inform your process controls
- They shape your regulatory specifications
- They protect your patients and your product
CQAs are the compass of development. Lose sight of them, and your formulation may look acceptable — but will fail under scrutiny.
Read also:
Resource Person: Moinuddin syed. Ph.D, PMP®
